Eli Lilly's LillyDirect opens a cash-pay route to obesity drugs
Direct cash-pay sales let patients buy GLP-1 obesity drugs without insurance, but the prices — $149 to $349 a month in early 2026 — still shape who can afford them [1].
In January 2024, Eli Lilly began selling its obesity medicines directly to patients who pay cash, through a service called LillyDirect. The company later added discounted single-dose vials of Zepbound (tirzepatide). About a year later, Novo Nordisk opened its own direct-ordering channel, and cash prices have become a standing part of how GLP-1 drugs are bought and sold [1].
Prices now vary by drug, dose and whether a patient uses insurance. As of January 2026, Novo Nordisk said the two lowest doses of the newly approved Wegovy pill (semaglutide) would cost $149 a month for people paying cash and not using insurance, and the two higher doses $299 a month. By comparison, the lowest dose of the Wegovy injection is $349 a month for cash payers. For patients whose insurance covers the drugs, out-of-pocket costs could be as low as $25 a month, according to the company [1].
Doctors watching the shift describe both opportunity and limits. "With so much product in the market, I hope the competition will further reduce prices," said Dr. Shauna Levy, medical director of the Tulane Weight Loss Center [1]. Dr. Daniela Hurtado Andrade, an endocrinologist at the Mayo Clinic in Jacksonville, Florida, said lower prices will most likely expand access. But she noted that the most dramatic weight loss in trials came at the highest dose, meaning people would likely have to pay more to lose more, and that even $149 a month is still too expensive for some patients. "It's something that needs to be discussed with patients," she said, "because they may have expectations that are not real" [1].
Oral options are arriving alongside the price changes. The FDA approved Novo Nordisk's Wegovy pill in December 2025, and it was expected to be widely available in January 2026 [1]. It must be taken every morning on an empty stomach. In a late-stage trial, people who kept to that schedule lost 16.6% of their body weight on average; that figure fell to 13.6% when the pill was not taken exactly as prescribed, Levy said [1]. A once-daily GLP-1 pill from Eli Lilly is expected to gain approval later in 2026 and can be taken at any time of day [1].
Why it matters for patients
Direct sales give patients a second route when insurance will not cover a GLP-1 drug, or when coverage comes with prior-authorization hurdles. The posted prices are set by the manufacturer rather than by a pharmacy counter, so a patient paying cash can compare a monthly figure before ordering. Those figures still differ sharply by dose and by product, and the companies can change them.
Affordability is not the only variable. If a daily pill is not taken on schedule, the trial results suggest results are weaker [1]. For people who prefer injections, the weekly shots remain available, and the lowest-dose Wegovy injection is priced higher for cash payers than the low-dose pills [1].
What the direct channels do not resolve has not been reported: whether the cash prices will hold through 2026, whether more insurers will add coverage, and how the arrival of pills will change injection prices.
What happens next
Novo Nordisk's Wegovy pill was expected to reach pharmacies in January 2026 [1]. Eli Lilly's daily GLP-1 pill is expected to be approved later in 2026 [1]. Lilly is also finishing clinical trials of retatrutide, a weekly injection that targets GLP-1 and GIP, the same two hormones targeted by Mounjaro and Zepbound, plus a third hormone called glucagon, which may further boost weight loss [1].
Sources
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.